| |
|
|
|
| |
UNDERGRADUATE EDUCATION |
|
1986-1991 |
Beijing Medical University* |
|
(*now: Beijing University Medical Center, BUMC) |
B.S. (Pharmacy) |
Beijing, P R China |
|
|
|
GRADUATE EDUCATION |
|
1991-1996 |
Peking Union Medical College & Chinese |
|
Academy of Medical Science |
Ph.D. (Pharmacology) |
Institute of Material Medica, |
|
Prof. GT Liu, Ph. D. Advisor |
|
|
|
POST-GRADUATE TRAINING |
|
1996-1997 |
Beijing Medical University (BUMC) |
|
Chinese National Opening Key Laboratory for Bionics and Nature Medicine
Principle Scientist, with Prof. LH Zhang
|
1997-2002 |
Department of Pharmacology |
|
University of South Alabama
College of Medicine
Post-doctoral Fellow, with Prof. W.J. Thompson |
1999 |
Cell Pathways, Inc, |
|
Horsham, PA
Visitor Scientist |
|
|
|
APPOINTMENTS |
|
| 01/2005-present |
Instructor
Department of Pharmacology
University of South Alabama
College of Medicine
Mobile, Alabama |
| |
|
10/2002 - 12/2004 |
Research Associate and Principle Investigator |
|
Department of Pharmacology & Center for
Lung Biology (core for cellular signaling
transduction and secondary messenger)
Univ. of South Alabama College of Medicine
Mobile, Alabama
|
5/1/2002 - 10/2002 |
Research Associate |
|
Department of Pharmacology
Univ. of South Alabama College of Medicine
Mobile, Alabama
|
7/1996 - 6/1997 |
Assistant Professor of Pharmacology |
|
Beijing Medical University (BUMC)
College of Pharmacy
Beijing, PR China |
|
|
|
PROFESSIONAL ORGANIZATIONS |
|
American Association for Cancer Research
(Associate member)
|
PUBLICATIONS |
|
| <ORIGINAL ARTICLES> |
- B Zhu, GT Liu YM Zhao, RS Wu, SJ Strada B. Chemosensitizing Multiple Drug Resistance of Human Carcinoma by Bicyclol Involves Attenuated P-glycoprotein, GST-P and Bcl-2. Cancer Biology and Therapy, 2006, 5, 536-543.
- B Zhu, LH Zhang, YM Zhao, JR Cui, SJ Strada. 8-Chloroadenosine induced HL-60 cell growth inhibition, differentiation and G1 arrest involves attenuated cyclin D1 and telomerase but up-regulated p21WAF1/CIP1. Journal of Cellular Biochemistry, 2006, 97:166-177.
- B Zhu,S Strada, T Stevens. Cyclic GMP-specific phosphodiesterase 5 regulates cell growth and apoptosis of pulmonary endothelial cells. American Journal Physiology: Lung Cellular and Molecular Physilogy, 2005;289:L196-L206.
- B Zhu, L Vemavarapu, WJ Thompson, SJ Strada. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cell. Journal of Cellular Biochemistry, 2005;94:336-350.
- B Zhu, JJ Kelly, L Vemavarapu, SJ Strada, WJ Thompson. Activation and induction of cyclic AMP phosphodiesterase (PDE 4) in rat pulmonary microvascular endothelial cells. Biochemical Pharmacology, 2004;68:479-491.
- WJ Thompson, T Ashikaga, JJ Kelly, L Liu, B Zhu, L Vemavarapu, SJ Strada. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochemical Pharmacology, 2002;63:797-807.
- WJ Thompson, GA Piazza, H Li, L Liu, J Fetter, B Zhu, G Sperl, D Ahnen, R Pamukcu. Exisulind induction of apoptosis involves guanosine 3’,5’-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated b-catenin. Cancer Research, 2000;60:3338-3342.
- B Zhu, GT Liu. Cytotoxicity of hydrogen peroxide on primary cultured rat hepatocytes and its mechanism. Chinese Journals of Pharmacology and Toxicology, 1996; 10(4):260-267.
|
| <SUBMITTED> |
- B Zhu, SJ Strada. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma and pulmonary/cardiovascular vessels (Review). Current Topics in Medicinal Chemistry, In Print.
- B Zhu, GT Liu YM Zhao, RS Wu, SJ Strada. Chemoprevention of a novel anti-hepatitis drug Bicyclol against diethylnitrosamine-induced preneoplastics in rat liver. To: Cancer Biology and Therapy.
- J Creighton, B Zhu, T Stevens. Phosphodiesterase 4D4 colocalization with membrane spectrin is essential for cAMP mediated barrier strength in pulmonary endothelial cells. To: Circulation Research.
|
<IN PREPARATION>
|
- B Zhu. PDE5 inhibitors in apoptosis, book chapter.
- B Zhu, J Creighton, T Stevens. PDE4D associated microtubule regulation in pulmonary endothelium.
- B Zhu, SJ Strada, T Stevens. Expression of cone-type inhibitory g-subunit of PDE6 in rat pulmonary endothelium correlated to cell growth inhibition.
- B Zhu, RS Wu, GT Liu Cytotoxicity of rat peritoneal neutrophils to rat heapatocytes in vitro cultured.
- B Zhu, RS Wu, GT Liu. Effects of schizanhenol and biphenyl dimethyl dicarboxylate (DDB) on hydrogen peroxide- and calcium inophore A23187-stimulated neutrophils- induced cytotoxicity to isolated rat hepatocytes.
|
|
| CURRENT MAJOR GRANT SUPPORT |
- Principal Investigator Cyclic GMP phosphodiesterase 5 in control of apoptosis and growth inhibition in lung endothelium. AHA Southeast BGIA, $110,000. (AHA-0665169B-01)
- OTHER RESEARCH SUPPORT: Ongoing support (active): PO1 HL 66299, 09/24/01-07/31/06. Lung Endothelial Cell Phenotypes, Project 1: Calcium inhibition cAMP in Endothelial Cell Permeability (PI: T Stevens). This project is targeting to study calcium inhibition cAMP formation decrease spectrin binding to F-actin important to increase lung endothelial cell permeability. I have been involved in the studies, to identify the possible role of cAMP-specific PDEs, e.g. PDE4, in regulating the signaling between intracellular cAMP and calcium in related processes.
|
| PATENTS |
|
1. “Method of using a novel phosphodiesterase in pharmaceutical screening to identify compounds for treatment of neoplasia”, by “Cell Pathways, Inc.”, USA Patent #: US 6,200,771 B1; Date of Patent: March, 13, 2001;
2. “Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds”. European patent, publication No.: EP 0 997 145 A1, in May 3, 2000 , by “Cell Pathways, Inc.”, and also same patent content applied in other countries, e.g. South Africa, China, Hong Kong and Turkey, are kept in process;
3. Diagnostic for neoplasia (peak B), Cell Pathways, Inc., United State patent application with “patent 2”, BHGL case number 3866/199 ( filed in Nov. 21, 1998);
4. “Packaged pharmaceuticals and methods for causing compounds and pharmaceutical compositions to be used as inhibitors of neoplastic lesions”, “Cell Pathways, Inc.” case number P180 ( filed in Oct. 18, 1999);
5. “Method for selecting compounds for inhibition of neoplastic lesions”, by “Cell Pathways, Inc.”, U.S. serial number 09/366,003 ( filed in Aug. 3, 1998); |
|
|
TECHNOLOGICAL SKILL |
|
Gene expression and regulation: |
PCR, RT-PCR, relative quantitative |
|
RT-PCR, Northern-blot, Western-blot, sequencing, cloning;
|
Cell biology and biochemistry: |
cell culture, primary cultured cell, |
|
immunofluorescence,
immunoprecipitated, phosphorylation assay for protein kinases, DEAE chromatography for protein isolation;
|
Molecular Pharmacology: |
kinetic study, activity and structure |
|
assay for drug, analogs and inhibitors;
|
Animal model manipulation: |
tumor and carcinogenesis models |
|
establishment in rats and mice and related assay and experiment in
pharmacology, histology, enzymology and molecular biology;
|
Specific area: |
Cancer, carcinogenesis, |
|
chemoprevention for carcinogenesis,
phospodieaterase and related cell signal transduction for cyclic
nucleotides and protein kinases, antisense methods, apoptosis,
and cell cycle;
|
Computer skills: |
normal and plot software, gene bank |
|
search and primers design,
peptide and GST-fusion protein design for raising antibodies; |
|
|
|
SECTION A: PRESENT WORK & ACTIVITIES |
|
Research Associate and Independently Principal Investigator, Department of Pharmacology and Lung Biology Center, University of South Alabama College of Medicine (USACOM), Octber, 2002-present. (In charge the research work for core of “cellular signaling transduction and secondary messenger” for CLB)
|
|
1) Identification and characterization of PDE5 in rat pulmonary endothelial cells;
2) The role of PDE5 in regulate the [cGMP]i increase induced cell growth inhibition, apoptosis, and anti-angiogenesis;
3) The role of PDE4 in signaling transduction of AC6 in rat pulmonary endothelial;
4) Mechanism studies in different types of PDEs expression and pharmacological targets in endothelium and cancer;
|
SECTION B: PAST WORKING EXPERIENCE & ACADEMY PRACTICE |
|
Research Associate and Post-doctoral Fellow, Department of Pharmacology, University of South Alabama College of Medicine (USACOM), July 1997-Octber, 2002.
|
|
• Using anti-sense approaches like vector-base transfection and SiRNA to knock-out PDE5 in human colon cancer cells and the further studies on its correlation to cancer cells’ apoptosis with the mechanism on cellular cGMP, PKG activation, and cell cycle progression;
• Perform a research study in department of pharmacology of USACOM for the characterization, pharmacological behavior and gene expression of phosphodiesterase (PDE) in endothelial, epithelial and carcinoma cells which associate the cell signal transduction and apoptosis;
• Be in charge of the mechanism study for a kind of new anti- and preventive drugs for human colon cancer or adenomatous polyposis coli (APC) in cooperation with the Cell Pathways. Inc. (CPI);
• A study of PDE4 regulatory activation in cultured pulmonary endothelial cells;
• A study of anticancer drugs on PDE expression in carcinoma cells and connecting with the mechanism of apoptosis;
• Participate a project of the role of PDE and its inhibitors in regulation of cardiovascular and pulmonary functions;
• Took part in and presented research posters at conferences of “Experimental Biology” 99-01 and “AACR annual meeting” 01-02;
• Took part in “Golden Research Conference: Cyclic Nucleotide Phosphodiesterase ” (New London, NH, June 12-14, 1998);
|
|
Assistant Professor, Chinese National Opening Key Laboratory for Bionics and Nature Medicine in Beijing Medical University (BUMC) College of Pharmacy, July 1996 - June 1997.
• Led a small research group mainly focus on the study of Molecular Biology and Pharmacology in the field of anti-cancer drugs, which associated with the gene expression and transformation, cell cycle, apoptosis, and telomerase, in Chinese National Opening Key Laboratory;
• Established Western-blot analysis method on cyclins and associated proteins expression and telomerase activity assay by TRAP-ELISA method in the same lab;
• A study on the growth inhibitory effect of anti-cancer drug 8-chloroadenosine on HL-60 cells, and associated mechanism with cell cycle arrest, cyclin D1 expression, and telomerase activity.
Ph.D. Candidate Researcher, Institute of Material Medica, Peking Union Medical College (PUMC), July 1993 - July June 1996.
• Completed a research program mainly focus on seven subjects:
1) In vivo, chemopreventive effect of an anti-hepatitis drug, SY-801, on diethylnitrosamine (DEN) induced rat preneoplastic lesions and its effect on glutathione S transferase pi (GSTp), oncogenes, PKCa and multiple drug resistance (Mdr-1) gene expressions;
2) In vitro, inhibitory effect of SY-801 on phorbol ester (TPA) and 3-methylenthane (3-MCA) co-induced malignant transformation in mice balb/c 3T3 cells and its associated mechanism in cell proliferation and gene expressions;
3) Denitrosation and dealkylation metabolisms of diethylnitrosamine and dimethylnitrosamine by hepatic microsomes from SY-801 treated normal rat and associated P450 catalytic function by HPLC method;
4) Effect of SY-801 on GSTs and P450 isoenzymes expression in normal rats liver;
5) Reversal effect of SY-801 on drug resistance in VinR KB and AdrR MCF-7 carcinoma cell lines and associated mechanism with Mdr-1, GST, GSH and Bcl-2;
6) Effect of SY-801 and other two compounds on hydrogen peroxide and stimulated peritoneal rat polymorphonuclear neutrophils (PMNs) induced cytotoxities to rat primary cultured hepatocytes;
7) Involvement the work for the approving of SY-801 as a new clinical drug in P R China used for anti-hepatitis, anti-hepatoma and chemoprevention for high-rate hepatitis B– induced carcinogenesis of hepatoma and got the government award for the study;
• Participated in two international scientific research conferences.
M.S. Student Researcher, Institute of Material Medica, Peking Union Medical College (PUMC), 1991 July-June 1993.
• Participated in some work of study anti-allergy and anti-asthma drugs;
• Finished the study in anti-oxidant effect of SY-801 and its effect on the activation of PMNs induced by four kinds of stimulants;
• Transfer to Ph.D. study in 1993.
B.S. Student Researcher, College of Pharmacy, Beijing Medical University, July 1986 – June 1991.
• Participated in a study of isolation of protein kinase A (PKA) from rat muscle and protein kinase C (PKC) from rat brains, January –June 1991;
• Mechanism study of some anti-cancer drugs on the activities of PKA and PKC, January –June 1991;
• Studied in clinical pharmacy, pharmacology, and pharmacodenymics in Beijing Medical University Hospital and industrial pharmaceutics in Beijing Pharmacuetical Inc., July 1990-January 1991;
• Accepted as graduate student by PUMC in July 199 |
|
|
